Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Stendörren in connection with a tap issue of SEK 300 million bonds
Mandate

Vinge has advised Stendörren in connection with a tap issue of SEK 300 million bonds

October 04, 2018 Banking and Finance

Vinge has advised Stendörren Fastigheter AB (publ) (“Stendörren”) in connection with a tap issue of SEK 300 million senior unsecured floating rate bonds. 

The bonds have a tenor of three years and a floating interest rate of three months Stibor plus 4.25 per cent. The proceeds from the subsequent bond issue will be issued for general corporate purposes. Swedbank has acted as Issuing Agent and financial advisor to Stendörren.

In accordance with the terms and conditions, the subsequent bonds are intended to be listed and admitted to trading on the corporate bond list at Nasdaq Stockholm shortly.

Vinge also advised Stendörren in connection with the company’s initial bond issue of SEK 350 million on 18 June 2018. A listing prospectus was approved by the Swedish Financial Supervisory Authority on 1 August 2018.

Vinges team consisted of Louise Brorsson Salomon, André Isacson and Fredric Reissmüller.

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025